Atrium Therapeutics (RNA) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Stablecoin Development is the larger company by market cap ($143.9 million vs $135.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNA | SDEV |
|---|---|---|
| Share price | $7.93 | $2.78 |
| Market cap | $135.65M | $143.87M |
| 1-day change | -0.75% | -14.46% |
| YTD return | — | -90.14% |
| 1-year return | — | -55.87% |
| 5-year return | — | -99.92% |
| EPS (TTM) | $-5.42 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.77 | $99.75 |
| 52-week low | $7.63 | $0.78 |
| Distance from 52-week high | -52.71% | -97.21% |
| Analyst consensus | none | — |
| Avg. price target upside | +215.26% | — |
| Average volume | 255.56K | 11.20M |
| Shares outstanding | 17.11M | 51.75M |
| Employees | — | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
RNA vs SDEV FAQ
Which is bigger, Atrium Therapeutics or Stablecoin Development?
Stablecoin Development (SDEV) is larger, with a market capitalization of $143.87M compared with $135.65M for Atrium Therapeutics (RNA).
Are Atrium Therapeutics and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.